percutaneous coronary interention
Showing 1 - 25 of >10,000
High-risk Percutaneous Coronary Intervention, Heart Disease, Coronary Trial (VITALYST System)
Not yet recruiting
- High-risk Percutaneous Coronary Intervention
- Heart Disease, Coronary
- VITALYST System
- (no location specified)
Nov 9, 2023
Atrial Fibrillation, Coronary Artery Disease Trial (Rivaroxaban)
Not yet recruiting
- Atrial Fibrillation
- Coronary Artery Disease
- (no location specified)
Oct 22, 2023
Coronary Artery Disease Trial in Toulouse (GUIDEX® guiding catheter, Launcher™ coronary guide catheter)
Not yet recruiting
- Coronary Artery Disease
- GUIDEX® guiding catheter
- Launcher™ coronary guide catheter
-
Toulouse, FranceCHU Toulouse
Aug 22, 2023
Coronary Artery Disease, Drug Coated-balloon, Intravascular Ultrasound Trial in Valencia (Drug coated-balloon percutaneous
Recruiting
- Coronary Artery Disease
- +5 more
- Drug coated-balloon percutaneous coronary intervention.
- Angiography-derived coronary physiology (IMRangio)
-
Valencia, SpainHospital Universitario y Politécnico La Fe
Oct 8, 2023
Percutaneous Coronary Intervention Versus Coronary Artery Bypass
Enrolling by invitation
- Coronary Stenosis
- Coronary Artery Disease
- percutaneous coronary intervention vs bypass graft surgery
-
Bad Krozingen, Baden Würtemberg, Germany
- +3 more
Jul 19, 2023
High-Risk Percutaneous Coronary Intervention Trial in Tbilisi (The Elevate™ System)
Active, not recruiting
- High-Risk Percutaneous Coronary Intervention
- The Elevate™ System
-
Tbilisi, GeorgiaIsraeli-Georgian Medical Research Clinic "Helsicore"
Oct 24, 2023
Coronary Artery Stenosis Trial in Seoul (State-of-the-Art Percutaneous Coronary Intervention, standard CABG)
Not yet recruiting
- Coronary Artery Stenosis
- State-of-the-Art Percutaneous Coronary Intervention
- standard CABG
-
Seoul, Korea, Republic ofAsan Medical Center
Apr 14, 2023
Coronary Artery Disease, Percutaneous Coronary Intervention Trial in Seoul (Percutaneous coronary intervention)
Recruiting
- Coronary Artery Disease
- Percutaneous Coronary Intervention
- Percutaneous coronary intervention
-
Seoul, Korea, Republic ofSamsung Medical Center
Nov 15, 2022
Patients Undergoing Percutaneous Coronary Intervention
Recruiting
- Acute Coronary Syndrome
- +3 more
-
Jinan, Shandong, ChinaJinan Central Hospital
Jan 31, 2023
Bleeding and Ischemic Risk
Completed
- Coronary Artery Disease
- Percutaneous Coronary Intervention
- Percutaneous coronary intervention
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Oct 13, 2023
Laboratory Indices to Left Ventricular Thrombus Formation in
Not yet recruiting
- Left Ventricular Thrombus
- Primary percutaneous coronary intervention or thrombolytic therapy
- (no location specified)
Nov 29, 2023
Percutaneous Coronary Intervention Trial in Seoul
Not yet recruiting
- Percutaneous Coronary Intervention
-
Seoul, Korea, Republic of
- +1 more
Aug 1, 2023
Coronary Artery Disease Trial in Ho Chi Minh City (Percutaneous Coronary Intervention)
Recruiting
- Coronary Artery Disease
- Percutaneous Coronary Intervention
-
Ho Chi Minh City, VietnamUniversity Medical Center
Oct 1, 2023
Coronary Artery Disease Trial in Ferrara, Naples (Cangrelor 50 MG)
Not yet recruiting
- Coronary Artery Disease
- Cangrelor 50 MG
-
Ferrara, Italy
- +1 more
Oct 13, 2023
Patients Undergoing Percutaneous Coronary Procedures
Not yet recruiting
- Coronary Artery Disease
- Coronary angiography and percutaneous coronary intervention
- (no location specified)
Nov 23, 2022
Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome Trial (Tafolecimab, Cholesterol Absorption Inhibitor,
Not yet recruiting
- Acute Coronary Syndrome
- Non ST Segment Elevation Acute Coronary Syndrome
- Tafolecimab
- +2 more
- (no location specified)
Oct 20, 2023
Coronary Microvascular Dysfunction Trial in Beijing (Bivalirudin, standard heparin)
Active, not recruiting
- Coronary Microvascular Dysfunction
- Bivalirudin
- standard heparin
-
Beijing, Beijing, ChinaPeking university first hospital
Aug 1, 2023
Coronary Artery Disease, Percutaneous Coronary Intervention Trial in Wuhan (Colchicine 0.5 MG, Colchicine 0.375 MG, Colchicine
Not yet recruiting
- Coronary Artery Disease
- Percutaneous Coronary Intervention
- Colchicine 0.5 MG
- +3 more
-
Wuhan, Hubei, ChinaDepartment of Cardiology, Union Hospital, Tongji Medical College
Oct 5, 2023
Coronary Artery Disease, Atherosclerosis Trial in Seoul (Percutaneous coronary intervention for complex lesion, Drug-eluting
Completed
- Coronary Artery Disease
- Atherosclerosis
- Percutaneous coronary intervention for complex lesion
- +3 more
-
Seoul, Korea, Republic ofSamsung Medical Center
Jan 16, 2023
Urinary Retention Trial in Istanbul (Modified Supine Position)
Not yet recruiting
- Urinary Retention
- Modified Supine Position
-
Istanbul, TurkeyBasaksehir Cam ve Sakura City Hospital
Sep 30, 2023
Coronary Artery Disease Trial (Routine Angiography Follow-up, Routine Clinical Follow-up)
Not yet recruiting
- Coronary Artery Disease
- Routine Angiography Follow-up
- Routine Clinical Follow-up
- (no location specified)
Jun 20, 2023
Multicenter Registry on Robotically Assisted PCI - TESLA
Recruiting
- Coronary Artery Disease
- Robotically-Assisted Percutaneous Coronary Intervention with CorPath GRX System
-
Nowy Sacz, Malopolska, PolandCentrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii
Apr 24, 2023
High-risk Percutaneous Coronary Intervention Trial in New York (The Elevate™ System)
Not yet recruiting
- High-risk Percutaneous Coronary Intervention
- The Elevate™ System
-
New York, New YorkNew York-Presbyterian Hospital/Columbia University Irving Medica
Feb 3, 2023
Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Coronary Artery Disease Trial in Bern (Algorithm-guided
Not yet recruiting
- Percutaneous Coronary Intervention
- +2 more
- Algorithm-guided DAPT duration
- Standard-of-care DAPT duration
-
Bern, SwitzerlandBern University Hospital
Feb 16, 2023
Percutaneous Coronary Intervention Optimization With Fractional
Completed
- Coronary Artery Disease
- +2 more
- IVUS guided PCI optimization
- +2 more
- (no location specified)
Feb 19, 2023